Palatin Technologies
Cedar Brook Corporate Center
4C Cedar Brook Drive
Cranbury
New Jersey
08512
United States
Tel: 609-495-2200
Fax: 609-495-2201
Website: http://www.palatin.com/
403 articles about Palatin Technologies
-
Palatin Technologies Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
8/17/2010
-
Palatin Technologies to Raise $2.0 Million Dollars in Registered Direct Offering
6/25/2010
-
Palatin Technologies Announces Last Patient Dosed and Database Lock in Subcutaneous Bremelanotide Trial in Men
6/24/2010
-
Palatin Technologies Announces Positive Preclinical Data with PL-3994 for Asthma Indications
6/21/2010
-
Palatin Technologies Reports Third Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on May 13, 2010
5/13/2010
-
Palatin Technologies To Report Fiscal Year 2010 Third Quarter Results; Teleconference and Webcast to be held on May 13, 2010
5/12/2010
-
Palatin Technologies Issued U.S. Patent and Receives Patent Allowance on Seven Additional Patents
5/4/2010
-
Palatin Technologies Receives $2.5 Million from AstraZeneca PLC
3/23/2010
-
Palatin Technologies To Raise $2.6 Million Dollars in Registered Direct Offering
2/25/2010
-
Palatin Technologies Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
2/16/2010
-
Palatin Technologies Announces Dosing of Subcutaneous Bremelanotide Trial in Men
2/9/2010
-
Palatin Technologies Issued U.S. Patent for Heart Failure Drug Candidate
12/1/2009
-
Palatin Technologies to Receive $5 Million from AstraZeneca PLC (JOBS)
9/29/2009
-
Palatin Technologies Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting
9/15/2009
-
Palatin Technologies Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting
9/15/2009
-
Palatin Technologies Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
9/8/2009
-
Palatin Technologies Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
8/12/2009
-
Palatin Technologies Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8/4/2009
-
Palatin Technologies to Present at Cowen Annual Health Care Conference on March 19, 2009
3/13/2009
-
Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US
3/5/2009